Perform a meta-analysis of CRTs for tacrolimus in atopic dermatitis published from 2005 to 2018 by Καραμπατζάκης-Κουρίτας, Αναστάσιος
 UNIVERSITY OF THESSALY 
SCHOOL OF MEDICINE 
LABORATORY OF BIOMATHEMATICS 
M.SC. "RESEARCH METHODOLOGY IN BIOMEDICINE, 






Perform a meta-analysis of CRTs for tacrolimus in atopic dermatitis 
published from 2005 to 2018. 
 
Karampatzakis Kouritas Anastasios 
 
Committee members  
Dr Doxani Chrisoula 
Prof. Stefanidis Ioannis 





LARISSA, SEPTEMBER 2018 
Institutional Repository - Library & Information Centre - University of Thessaly
07/06/2020 18:18:21 EEST - 137.108.70.13
ΠΑΝΕΠΙΣΤΗΜΙΟ ΘΕΣΣΑΛΙΑΣ 
ΣΧΟΛΗ ΕΠΙΣΤΗΜΩΝ ΥΓΕΙΑΣ 
ΕΡΓΑΣΤΗΡΙΟ ΒΙΟΜΑΘΗΜΑΤΙΚΩΝ 
ΠΡΟΓΡΑΜΜΑ ΜΕΤΑΠΤΥΧΙΑΚΩΝ ΣΠΟΥΔΩΝ  






ΘΕΜΑ ΔΙΠΛΩΜΑΤΙΚΗΣ ΕΡΓΑΣΙΑΣ 
Πραγματοποίηση μεταανάλυσης για την φαρμακευτική ουσία 
τακρόλιμους σε ασθενείς με ατοπική δερματίτιδα, σε κλινικές 
μελέτες οι οποίες δημοσιεύτικαν το διάστημα 2005 μέχρι 2018. 
 
Καραμπατζάκης Κουρίτας Αναστάσιος 
 
Μέλη της επιτροπής 
Δρ Δοξάνη Χρυσούλα 
Καθ. Στεφανίδης Ιωάννης 




ΛΑΡΙΣΑ, ΣΕΠΤΕΜΒΡΗΣ 2018 
Institutional Repository - Library & Information Centre - University of Thessaly
07/06/2020 18:18:21 EEST - 137.108.70.13
Contents 
1. INTRODUTION ................................................................................................................. 1 
1.1 Atopic dermatitis ....................................................................................................... 1 
1.2 Pharmaceutical substances used in studies .............................................................. 1 
1.2.1 Tacrolimus ointment 0.1% & 0.03% .................................................................. 1 
1.2.2 Pimecrolimus cream 1% .................................................................................... 1 
1.2.3 Methylprednisolone aceponate ointment 0.1% ............................................... 2 
1.2.4 Hydrocortisone butyrate ointment 0.1% .......................................................... 2 
1.3 AIM OF THE STUDY .................................................................................................... 2 
2 MATERIALS AND ΜETHODS............................................................................................... 3 
2.1 Literature search ...................................................................................................... 3 
2.2 Study selection ......................................................................................................... 3 
2.3 Exclusion criteria ..................................................................................................... 3 
2.4 Statistical formulas used ........................................................................................... 3 
2.5 Data extraction ......................................................................................................... 5 
2.6 Statistical analysis .................................................................................................... 5 
3 RESULTS ........................................................................................................................... 6 
3.1 Results explanation ................................................................................................... 7 
3.2 Heterogeneity ............................................................................................................ 7 
3.3 Publication bias ......................................................................................................... 8 
4 Limitations ......................................................................................................................... 9 
4.1.1 Number of studies ............................................................................................. 9 
4.1.2 Heterogeneity .................................................................................................... 9 
5 References ....................................................................................................................... 10 
6 Appendix .......................................................................................................................... 11 
 
  
Institutional Repository - Library & Information Centre - University of Thessaly
07/06/2020 18:18:21 EEST - 137.108.70.13
Perform a meta-analysis of CRTs for tacrolimus in atopic dermatitis 
published from 2005 to 2018. 
University of Thessaly Faculty of Medicine, Laboratory of Biomathematics 
 
Abstract 
Background: Atopic dermatitis (AD) is a skin condition which is characterised by 
redness and pruritus, That condition effects the quality of life for the patients whom 
are suffering. There is not known the cause of the illness or the cure as well. The first 
line treatment for AD was corticosteroids but for chronic, physicians suggested 
topical calcineurin inhibitors, such as pimecrolimus and tacrolimus ointments, to 
avoid corticosteroids side effects. 
Aim: In order to ensure that tacrolimus, the most common calcineurin inhibitor is 
more effective than any other treatment a meta-analysis was performed in clinical 
trials from 2005 to 2018 which were testing the tacrolimus efficacy versus other 
known treatments. 
Methods: Literature research was performed in the following databases, Cochrane 
Central Register of Controlled Trials (CENTRAL), LILACS Global Resource of 
Eczema Trials and Pub Med databases, in order to detect related papers. Odd ratio and 
forest plot were calculated to present the results. Egger test was performed to identify 
publication bias. 
Results: Tacrolimus ointment is more effective, in contents of 0.1% and 0.03%, 
compared with other topical treatments in adults and adolescents. 
 Conclusion: According to the meta-analysis performed, there is statistically 
significant difference for most of the studies which include both adults and paediatric 
patients with AD, with  tacrolimus being more effective than other treatments in any 
concentration. 
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Πραγματοποίηση μεταανάλυσης για την φαρμακευτική ουσία 
τακρόλιμους σε ασθενείς με ατοπική δερματίτιδα, σε κλινικές 
μελέτες οι οποίες δημοσιεύτικαν το διάστημα 2005 μέχρι 2018. 
Πανεπιστημιο Θεσσαλιας Σχολη Επιστημων Υγειας, Εργαστήριο Βιομαθηματικών 
Περίληψη 
Ιστορικό: Η ατοπική δερματίτιδα (ΑΔ) είναι μια κατάσταση του δέρματος που 
χαρακτηρίζεται από ερυθρότητα και κνησμό, η οποία επηρεάζει την ποιότητα ζωής 
των ασθενών που υποφέρουν. Δεν είναι γνωστό ποιο είναι το αίτιο αυτής της 
ασθένειας και δεν υπάρχει γνωστή θεραπεία. Η θεραπεία πρώτης γραμμής για την ΑΔ 
είναι τα κορτικοστεροειδή, αλλά για χρόνια χρήση, οι γιατροί προτείνουν τοπικούς 
αναστολείς καλσινευρίνης, όπως αλοιφές πιμεκρόλιμους και τακρόλιμους, για την 
αποφυγή των παρενεργειών των κορτικοστεροειδών. 
 
Στόχος: Προκειμένου να διασφαλιστεί ότι η τακρόλιμους, ο πιο κοινός αναστολέας 
καλσινευρίνης, είναι πιο αποτελεσματικός από οποιαδήποτε άλλη θεραπεία, 
πραγματοποιήθηκε μετα-ανάλυση στις κλινικές δοκιμές από το 2005 έως το 2018, οι 
οποίες δοκιμάζουν την αποτελεσματικότητα της τακρόλιμους έναντι άλλων γνωστών 
θεραπειών. 
 
Μέθοδοι: Οι μέθοδοι που χρησιμοποιήθηκαν ήταν η βιβλιογραφική έρευνα στις  
Cochrane Central Register of Controlled Trials (CENTRAL), LILACS Global 
Resource of Eczema Trials and Pub Med βάσεις δεδομένων, ανίχνευση σχετικών 
δημοσιευμένων εγγράφων και ανάλυση του συνόλου των επιστημονικών 
δημοσιεύσεων για την ανίχνευση της συνολικής αναλογίας πιθανότητας και η 
δημιουργία ενός forest plot για την παρουσίαση των αποτελεσμάτων. 
 
Αποτελέσματα: Το σκεύασμα τακρόλιμους σε αλοιφή είναι πιο αποτελεσματικό σε 
οποιαδήποτε περιεκτικότητα σε σύγκριση με άλλες θεραπείες σε ενήλικες και 
εφήβους. 
 
 Συμπέρασμα: Από την πραγματοποιηθείσα μετα-ανάλυση προκύπτει ότι οι 
περισσότερες από τις μελέτες που περιλαμβάνουν τόσο ενήλικες όσο και 
παιδιατρικούς ασθενείς με ΑΔ έχουν ως αποτέλεσμα ότι η τακρόλιμους είναι πιο 
αποτελεσματική από άλλες θεραπείες σε οποιαδήποτε συγκέντρωση. 
 
Λέξεις κλειδιά: ατοπική δερματίτιδα, μετα-ανάλυση, τακρόλιμους  
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1.1 Atopic dermatitis 
Atopic dermatitis is a chronic, relapsing, skin disease which effects the patients’ 
quality of life and productivity.  It appears with skin inflammation and it is 
characterised by pruritus,  swollen, red  and cracked skin. As a condition tends to flare 
periodically and may be accompanied by asthma or hay fever. Patients with atopic 
dermatitis often appear food allergies (Caproni; et al.   2007). 
There is not known cause of atopic dermatitis, although genetic factors, immune 
system dysfunction and environmental exposures believed to be involved. People 
leaving in urban areas and dry climates appear to have higher rate to appear the 
symptoms of the disease. Stress can influence the symptoms but it does not consider 
as a cause (A.Kirschbaum; et al.2002). 
There is not deference in the rate that both sexes are affected. A higher ratio occur for 
younger children to disease than adults, although there is a persist into adulthood in a 
30% estimation of the cases. 
Treatment involves a good management of anything conjuncts with flares of the 
disease and attempt to extend the remission periods between the flares. Management 
involves avoid skin contact with irritant factors such as wool clothing or perfumes, 
daily baths and moisturising cream application, usage of topical steroids and 
medication for pruritus as a first line treatment and long term usage of calcineurin 
inhibitors (Kirsner; et al. 2010) 
. 
1.2 Pharmaceutical substances used in studies 
 
1.2.1 Tacrolimus ointment 0.1% & 0.03%  
Tacrolimus ointment is a drug for external use for truck and limps. It is working by 
suppresses the immune system and the inflammation by inhibiting the enzyme 
calcineurin which is crucial for the multiplication of T-cells, cells that are required for 
activation of the immune system. Tacrolimus was discovered in 1987 and  tacrolimus 
ointment was approved for the treatment of atopic dermatitis in December 2000 
(Paller; et al. 2005). 
1.2.2 Pimecrolimus cream 1% 
Pimecrolimus is an immunomodulating agent of the calcineurin inhibitor class used in 
the treatment of atopic dermatitis. Pimecrolimus, like tacrolimus, belongs to the 
ascomycin class of macrolactam immunosuppressives, acting by the inhibition of T-
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cell activation by the calcineurin pathway and inhibition of the release of numerous 
inflammatory cytokines. Pimecrolimus has a similar mode of action to that of 
tacrolimus (Fleischr; et al.2007) 
   
1.2.3 Methylprednisolone aceponate ointment 0.1% 
Methylprednisolone aceponate is a glucocorticosteroid used to suppress the immune 
system and decrease inflammation. This drug is working by crossing cell membranes 
and bind with high affinity to specific cytoplasmic receptors, modifying transcription 
and protein synthesis. By this mechanism, Methylprednisolone aceponate  can inhibit 
leukocyte infiltration at the site of inflammation, interfere with mediators of 
inflammatory response, and suppress humoral immune responses. 
Long-term use of methylprednisolone aceponate, as with all corticosteroids, can be 
associated with numerous of side effects as for instance swelling of face, weight gain, 
osteoporosis (Bieber; et al. 2007) 
1.2.4 Hydrocortisone butyrate ointment 0.1% 
Hydrocortisone butyrate is a corticosteroid belongs to the class of steroid hormones 
that are produced in the adrenal cortex of vertebrates. This medication is used to treat 
a variety of skin conditions as for example eczema, atopic dermatitis and allergies. 
Hydrocortisone butyrate stimulate the lipocortin-1 escaping to the extracellular space, 
where it binds to the leukocyte membrane receptors and inhibits various inflammatory 
events such as epithelial adhesion, chemotaxis, phagocytosis, and the release of 
various inflammatory mediators from neutrophils, macrophages and mastocytes. 
Additionally the immune system is suppressed by hydrocortisone butyrate due to a 
decrease in the function of the lymphatic system, a reduction in immunoglobulin and 
complement concentrations, the precipitation of lymphocytopenia, and interference 
with antigen-antibody binding (Reitamo; et al.2005) 
1.3 AIM OF THE STUDY 
The purpose of the study was to perform a meta-analysis in the clinical research trials 
between 2005 and  2018 which are testing tacrolimus, the most common calcineurin 
inhibitor versus other treatments sush as Hydrocortisone butyrate ointment 0.1%, 
Methylprednisolone aceponate ointment 0.1% and Pimecrolimus cream 1% in order 
to identify that tacrolimusis more effective than any other treatment. 
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2 MATERIALS AND ΜETHODS 
2.1  Literature search 
All of the studies, published between July 2005 and 2018 were found after literature 
research in online databases in particular Cochrane Central Register of Controlled 
Trials (CENTRAL), LILACS Global Resource of Eczema Trials and Pub Med. 
The research took place by searching for the following terms: atopic dermatitis, atopic 
eczema, tacrolimus, more effective, versus, compare, efficacy, pimecrolimus, 
glucocorticosteroids and corticosteroids.  
2.2 Study selection 
All of the articles were screened by title or abstract. If none of the exclusion criteria 
were satisfied, the article was candidate to be used in the present study. 
 Some studies used scoring systems with different diagnostic standards. Those studies 
were screened by reading the ‘materials and methods’ section of the papers. If there 
were general similarities with the majority of the studies, they were included. 
The articles should compare tacrolimus ointment in any dilution, with other 
calcineurin inhibitors or corticosteroids, which are known to be effective in atopic 
dermatitis treatment.  
All the studies published between 2005 and 2018. 
2.3  Exclusion criteria 
To insure the efficacy of the meta-analysis and minimise the heterogeneity of the 
study were created some cut off points, thus a number of studies was eliminated. 
1. Studies that were comprised research in specific human race. 
2. Studies that published before 2005. 
3. Studies were the participants include infants.  
 
4. Studies that were comparing tacrolimus with placebo were not included, since 
several studies had already proven the drug efficacy in this scenario. 
 
2.4 Statistical formulas used 
For the statistical analysis from the data given from the selected researches, extracted 
the number of participants of each group, tacrolimus group and control group, and the 
number of patients that treatment was successful for them. By transmitting these data 
to binary outcomes made possible to find the odds ratio of each treatment and the total 
odds ratio of all treatments combined. 
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Then the Random Effect (RE) model used to synthesise the results so the overall 
estimation could be explored, because there is genuine diversity in the studies, as they 
are compare tacrolimus with different alternative treatments and the age groups are 





For RE model if the unite is not included in the odds ratio for 95% confidence interval 
the result is significant. 
In order to examine the heterogeneity of the studies the following statistical formula 
has been used.  
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2.5  Data extraction 






Scoring system Total cases Total 
controls 




Fleischer 2007 2007 39.65 Hanifin & Rajka 
*IGA 
141 140 
Paller 2005 2005 19.1 Hanifin & Rajka 
*IGA 
528 532 
Kirsner 2010 2010 17.8 Hanifin & Rajka 
*IGA 
171 176 
Bieber 2007 2007 7.65 *IGA 130 127 
*Investigator Global Assessment for Atopic Dermatitis (IGA) 
 
2.6 Statistical analysis 
The main purpose of the present study was to juxtapose the potency of tacrolimus 
with other approved treatments for atopic dermatitis. After literature investigation 
were completed and data were extracted from the papers chosen, in order to estimate 
the overall difference between tacrolimus and the other known treatments, meta-
analysis statistical formulas had to be done. 
Odds ratio of each study used to perform a forest plot and present graphically the total 
result after categorising all data that had been extracted binomially. 
Thus, prior to synthesis of the results from each individual research, the odds ratio 
specified as measure to be possible to calculate the differences. The random effects 
model (RE) has been used, as genuine diversity existed between the clinical trials.  
The publication bias calculated with funnel plot, performed with IBM SPSS version 
24 software and with Egger’s test (Egger lee 2015) 
All calculations made by using the excel formula provided by M.SC. course 
"Research Methodology In Biomedicine, Biostatistics And Clinical Bioinformatics"  
(Zintzaras 2010). 
The results were graphical displayed by a forest plot made with the IBM SPSS 
version 24 software and by DistillerSR online tool. 
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From a total of 2917 patients that were randomised in these five selected studies, 
where tacrolimus was compared with other topical treatments, the result was that 
there is statistical significant difference between tacrolimus and other treatments, with 
tacrolimus appear to be more effective. 
 
In the following charts there is a summarise of the results in forest plots.
 










Paller 2005 1.57 1.18 2.07 0.45 6.957 3.117 
Fleischer 2007 2.17 1.20 3.92 0.77 3.306 2.557 
Kirnser 2010 1.74 1.01 2.99 0.55 3.631 2.012 
Bieber 2007 1.11 0.66 1.89 0.11 3.710 0.395 
Reitamo 2005 2.28 1.75 2.97 0.82 7.385 6.077 
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3.1 Results explanation 
From the five studies selected, only two of them Reitamo et al 2005 and Bieber et al 
2007,were compared tacrolimus versus ointments that contain steroids and the other 
studies (Kirnseret al  2010, Paller et al  2005 and Fleischer et al 2007) were compared 
tacrolimus versus pimecrolimus cream.  
All the studies apart of Bieber et al 2007were included only adult patients or adult and 
pediatric patients, but Bieber et al 2007 was included  children and adolescents. 
The pooled estimation of the studies have as result that tacrolimus ointment has 
statistically significant better results that treatments compared with. 
All the studies with odds ratio over 1.00 have as statistically significant result that 
tacrolimus is better than the opposite treatment. The lower limit of the confidence 
interval for the study Kirnser et al 2010 is touching axis of one, so the result 
ismarginally statistically significant.  
The confidence interval for Bieber’sstudy2007 crossed the axis of one so the result is 
not statistically significant. 
In forest plots in general the bigger the square of a study is, the weightier the study is, 
that shows, according to DistillerSR online tool, that Paller 2005 is the most weighted 
study and Fleischer 2007 the less weighted study. 
The same studies have the smallest and biggest confidence interval vice versa. 
3.2 Heterogeneity 
By using, the statistical formula presented in chapter ‘Statistical formulas used’ a P-
value of 0.057 found. That result confirm statistically significant heterogeneity, 
because if P-value < 0.10 significant heterogeneity exists. This result can be explained 
by theory, as the treatments compared with tacrolimus are not the same for all papers 
selected. 
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3.3 Publication bias 
In order to accept the results a publication bias test should take place to ensure that 
not only papers with significant results were selected to be analysed for the meta-
analysis. 
Therefore the common used funnel plot had been used, because it is easier to be red, 
as the results appear graphically in a chart. 
Hence the SPSS version 24 software had been used by adding the theta and the 
precision of each study and perform the graph. 
Theta = θi=ln(ORi) 
 
Precision = 1/SEi 
 
 
The graph predisposes us for not publication bias, but because of the small number of 
the studies, it is not clear if publication bias exists. 
 
For that reason an Egger’s test performed next, to insure that publication bias does not 
exist. 
 
To complete the Egger’s test with SPSS version 24 software, θi√wi and √wi had been 
used. 
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Because P-value = 0.570 ≥ 0.05 it is safely proven that there is not publication bias. 
 
4 Limitations 
The limitations of  the study that have to be mentioned are mainly two, the number of 
studies and the heterogeneity.  
4.1.1 Number of studies 
The number of the studies selected can be considered as small and that fact can lead in 
high heterogeneity. 
4.1.2 Heterogeneity  
The heterogeneity observed between the studies is high, and that is because of the 
small number of the studies and the differences between what studies are comparing. 
The studies Reitamo 2005 and Bieber 2007 are comparing tacrolimus with ointments 
which contain steroids, the other tree studies compare tacrolimus with pimecrolimus. 
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The other heterogeneity limitation that is observed in the study is that Bieber 2007 
study does include only children and adolescents patients counter to the other four 
studies. 
A subgroup analysis can be proposed for further investigation. 
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6 Appendix  
 
Calculations with excel provided by M.SC. course "Research Methodology In Biomedicine, 
Biostatistics And Clinical Bioinformatics"  (Zintzaras.2010). 
 
IBM SPSS version24 software used to built forest plot.  
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IBM SPSS version24 software used to built funnel plot. 
 
IBM SPSS version24 software used to perform Egger’s test. 
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